Valuation dashboard for TransMedics Group, Inc. (TMDX) with P/E N/A, P/B N/A, EV/EBITDA N/A and dividend yield N/A. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs.
Analysis Summary
TransMedics Group, Inc. reported revenue of $605.5M in the most recent fiscal year, growing at a 5-year CAGR of 88.2%.
Balance sheet quality for TMDX: current ratio of 7.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Models
| DCF Fair Value | $-1,120.75 |
| vs Current Price | -1,450.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| TMDX | TransMedics Group, Inc. | $2.9B | |||
| KYMR | Kymera Therapeutics, Inc. | $8.8B | 6.99 | -21.5% | |
| BRKR | Bruker Corporation | $9.7B | 4.01 | -2.9% | |
| IMVT | Immunovant, Inc. | $6.9B | 9.40 | -69.6% | |
| NAMS | NewAmsterdam Pharma Company N.V. | $2.7B | 4.53 | -38.3% | |
| INDV | Indivior Pharmaceuticals Inc | $4.5B | 12.57 | -214.3% | |
| GKOS | Glaukos Corporation | $9.4B | 14.02 | -28.6% | |
| HNGE | Hinge Health, Inc. | $7.6B | 72.46 | 22.33 | 30.2% |
Price
| Price | $82.99 |
| Market Cap | $2.9B |
| Exchange | NASDAQ |
| Country | US |
Related companies: AKRO · BRKR · GKOS · HNGE · IMVT · INDV · KYMR
Explore sector: Healthcare · Medical - Devices
More sections of TMDX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks